{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=33", "query": { "intervention": "Sequence", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 2514, "total_pages": 252, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T21:54:14.007Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03808298", "title": "Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Balovaptan therapeutic dose Treatment A", "type": "DRUG" }, { "name": "Balovaptan supra-therapeutic dose Treatment B", "type": "DRUG" }, { "name": "Active control [moxifloxacin] on Day 2 Treatment C", "type": "DRUG" }, { "name": "Active control [Moxifloxacin] on Day 15 Treatment D", "type": "DRUG" }, { "name": "Placebo for Balovaptan Treatment C", "type": "DRUG" }, { "name": "Placebo for Balovaptan Treatment D", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment A", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment B", "type": "DRUG" }, { "name": "Moxifloxacin Treatment C", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment C", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin Treatment D", "type": "DRUG" }, { "name": "Moxifloxacin Treatment D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 57, "start_date": "2019-02-07", "completion_date": "2019-07-13", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03808298" }, { "nct_id": "NCT07017816", "title": "A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "CNS Malignancies", "Medulloblastoma Recurrent", "ATRT Recurrent", "Pineoblastoma", "Embryonal Neoplasm", "Ependymoma Recurrent", "High Grade Gliomas" ], "interventions": [ { "name": "SGT-53", "type": "DRUG" }, { "name": "hypofractionated radiotherapy with immunotherapy", "type": "RADIATION" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 18, "start_date": "2025-12-16", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07017816" }, { "nct_id": "NCT00116844", "title": "VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infections, Herpesviridae" ], "interventions": [ { "name": "Valaciclovir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2005-03-29", "completion_date": "2006-01-10", "has_results": true, "last_update_posted_date": "2018-02-12", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 17, "location_summary": "Carmichael, California • Davis, California • Riverside, California + 13 more", "locations": [ { "city": "Carmichael", "state": "California" }, { "city": "Davis", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116844" }, { "nct_id": "NCT04188834", "title": "Effects of Sensory Flicker and Electrical Flicker Stimulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Diseases" ], "interventions": [ { "name": "Customized version of DAVID device", "type": "DEVICE" }, { "name": "Blackrock CereStim", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2020-01-10", "completion_date": "2022-11-22", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04188834" }, { "nct_id": "NCT07266363", "title": "Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "ESCC" ], "interventions": [ { "name": "Small RNA sequencing of exo- and cf-miRNAs", "type": "DIAGNOSTIC_TEST" }, { "name": "RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay)", "type": "DIAGNOSTIC_TEST" }, { "name": "PCR-based validation (SYNERGY assay)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2025-01-15", "completion_date": "2028-06-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Monrovia, California", "locations": [ { "city": "Monrovia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266363" }, { "nct_id": "NCT06768658", "title": "A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nausea and Vomitting" ], "interventions": [ { "name": "TAK-951", "type": "DRUG" }, { "name": "TAK-951 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 1, "start_date": "2022-03-02", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06768658" }, { "nct_id": "NCT05836506", "title": "A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-903 Tablet Form 1", "type": "DRUG" }, { "name": "ABBV-903 Tablet Form 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2023-04-18", "completion_date": "2023-06-20", "has_results": false, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836506" }, { "nct_id": "NCT05923411", "title": "A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Single dose of PF-07220060 as first Tablet Formulation", "type": "DRUG" }, { "name": "Single dose of PF-07220060 as second Tablet Formulation", "type": "DRUG" }, { "name": "Single dose of PF-07220060 as a Tablet Formulation", "type": "DRUG" }, { "name": "Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration", "type": "DRUG" }, { "name": "Single dose of PF-07220060 as third tablet formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 113, "start_date": "2023-07-11", "completion_date": "2024-07-19", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05923411" }, { "nct_id": "NCT04740814", "title": "A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 33, "start_date": "2021-02-11", "completion_date": "2022-06-27", "has_results": true, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Covina, California • Upland, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740814" }, { "nct_id": "NCT03095638", "title": "Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Conventional dolutegravir 10 mg tablet", "type": "DRUG" }, { "name": "Conventional dolutegravir 50 mg tablet", "type": "DRUG" }, { "name": "Dispersible dolutegravir 5 mg tablet", "type": "DRUG" }, { "name": "Conventional dolutegravir 25 mg tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2017-05-03", "completion_date": "2017-06-23", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-11-07T21:54:14.007Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095638" } ] }